ReviewJournal of Parkinson's disease2026
Unmet needs in the pharmacological management of motor symptoms in Parkinson's disease.
Review in Journal of Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- The road towards faster development of novel pharmacotherapies for persons with Parkinson's disease.Journal of Parkinson's disease · 2026Article
- Advancing the Treatment of Motor Fluctuations in Parkinson's Disease with a Next-Generation Levodopa/Carbidopa Formulation.Neurology and therapy · 2026Review
- Editorial: Parkinson's disease: current findings and challenges in diagnosing and treating motor and non-motor symptoms.Frontiers in aging neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder clinically defined by the presence of cardinal motor features like bradykinesia, rigidity and resting tremor. The mainstay of PD treatment is pharmacological dopamine substitution and responsiveness of motor symptoms to levodopa is a supporting diagnostic feature of this illness. Although the armentarium of drugs to treat the motor symptoms of PD and their efficacy on a variety of motor problems are overall impressive, significant unmet needs persist, particularly in the advanced stages of PD. These include situations of poorly responsive tremor, motor complications associated with sustained levodopa exposure, disorders of gait and balance as well as impairments of posture, speech and swallowing. This review provides an overview of available treatment strategies for these areas of unmet need and emerging therapies under development. Future perspectives include novel pharmacological targets, new modes of drug delivery, combination therapies and the integration of real-time monitoring and wearable technologies to tailor treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.